Chemotherapy Shortages Deepen Even as Total Active Drug Gaps Hold at 225
Chemotherapy supply problems worsened in the third quarter, pushing cancer drug shortages higher even though the total number of active U.S. drug shortages remained flat at 225. The latest quarterly data from ASHP show how a stable headline figure can hide a more dangerous shift inside the supply chain: oncology products are taking a harder hit, and some of the drugs most difficult to substitute are the ones under pressure.
A flood at a Pfizer manufacturing site in India sits at the center of the latest disruption. The facility produced generic chemotherapy agents used for leukemia, Hodgkin lymphoma, colorectal cancer, pancreatic cancer, testicular cancer and other malignancies. Pfizer expects the interruption to last into 2028, a timeline that turns a manufacturing accident into a long clinical problem for infusion centers, pharmacies and oncology teams already stretched thin.
The practical effect is blunt. When a regimen depends on a drug with limited substitutes, a shortage can force treatment delays, dose changes or regimen changes that ripple across the entire cancer care pathway.
Why Oncology Is Absorbing the Heaviest Pressure
Several of the affected agents were already in shortage before the latest quarter closed. Ifosfamide, used in testicular cancer, remains one of the drugs most often affected, and cancer centers have identified ifosfamide and carboplatin among their most common shortages. Children’s hospitals have described chemotherapy as their largest concern because there are few practical alternatives when a standard agent disappears from inventory.
That lack of redundancy makes oncology uniquely vulnerable. In many other therapeutic areas, one product can be replaced with another in the same class. Cancer treatment is often less forgiving. Regimens are built around specific timing, cumulative dosing and narrow therapeutic windows, and drug interruptions can complicate cure-oriented care just as much as palliative treatment. For patients receiving multi-agent therapy, even a short gap in supply can derail cycle scheduling and create avoidable uncertainty at the bedside.
Shortages may delay care for some patients with cancer, and the problem does not stop with oncology drugs. Patients living with chronic pain or ADHD face parallel disruptions because 16% of active shortages involve controlled substances. The broader pattern matters because it shows the same supply fragility affecting highly specialized cancer medications and common outpatient drugs used every day.
Imaging Agents, Demand Surges and the Hidden Load on Pharmacies
Contrast agents used in CT scans, MRI studies and other critical procedures now make up 10% of all new shortages in 2026. That may sound separate from chemotherapy, but in real-world oncology it is tightly connected. Cancer care depends on imaging for staging, treatment planning, surveillance and response assessment. When contrast supply tightens, diagnostic bottlenecks can slow the entire chain of care, from first scan to treatment decision.
ASHP also pointed to shortages driven by sudden increases in demand, including estradiol patches. Demand spikes are a different kind of supply shock than a factory shutdown, but the clinical effect is similar: patients can be left without treatment even when the medication itself is not complicated to make. In shortage management, the reason for the gap matters less to the patient than the result at the pharmacy counter.
The pace of new shortages remains unsettling. Through September, 87 new shortages had already been documented, nearly matching the 89 reported across all of 2025. Active shortages are still far below the record 323 reached in early 2024, and second-quarter data showed 227. The overall level may have retreated from that peak, yet the distribution of shortages continues to move toward medications that are difficult to replace safely.
Manufacturing Policy, Staffing Strain and the Coming Supply Shift
ASHP calls for reshoring and nearshoring medication manufacturing, along with incentives that would steer purchasing toward vulnerable medications through long-term contracts. The logic is straightforward: if production is concentrated in too few facilities, one weather event, quality problem or geopolitical disruption can send shock waves through the market for years. Oncology drugs magnify that risk because they are not optional, and delays can change outcomes for patients with time-sensitive disease.
Federal efforts are beginning to move in the same direction. A new initiative is being developed to shift production of 86 essential medicines to the United States within 18 months. The scale of that plan suggests recognition that drug shortages are no longer a niche pharmacy issue; they are a national care-delivery problem with direct consequences for cancer treatment, imaging access and inpatient operations.
Even so, production policy is only part of the burden. Managing shortages adds to pharmacy staffing strain at a moment when health systems are already trying to do more with fewer people. Every shortage requires review of inventory, therapeutic alternatives, prescriber communication, procurement work and patient counseling. In oncology, those tasks are especially demanding because the margin for error is narrow and the consequences of delay can be severe.
The result is a supply system that remains fragile despite some improvement from the worst levels of early 2024. Chemotherapy shortages are worsening inside that fragile system, and the most vulnerable drugs are often the ones that cancer care cannot easily absorb. Until manufacturing becomes more resilient and procurement becomes less volatile, oncology teams will keep managing a problem that reaches far beyond the pharmacy shelf.